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Abstract 
The accurate assessment and communication of the severity of acute allergic reactions is important 
to patients, clinicians, researchers, the food industry, public health and regulatory authorities. 
Severity has different meanings to different stakeholders with patients and clinicians rating the 
significance of particular symptoms very differently. Many severity scoring systems have been 
generated, most focusing on the severity of reactions following exposure to a limited group of 
allergens. They are heterogeneous in format, none has used an accepted developmental approach 
and none has been validated. Their wide range of outcome formats has led to difficulties with 
interpretation and application. Therefore there is a persisting need for an appropriately developed 
and validated severity scoring system for allergic reactions that works across the range of allergenic 
triggers and addresses the needs of different stakeholder groups. We propose a novel approach to 
develop and then validate a harmonized scoring system for acute allergic reactions, based on a data-
driven method that is informed by clinical and patient experience and other stakeholders’ 
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perspectives. We envisage two formats: (i) a numerical score giving a continuum from mild to severe 
reactions that is clinically meaningful and is useful for allergy healthcare professionals and 
researchers; and (ii) a three grade based ordinal format that is simple enough to be used and 
understood by other professionals and patients. Testing of reliability and validity of the new 
approach in a range of settings and populations will allow eventual implementation of a 
standardized scoring system in clinical studies and routine practice. 
 
Introduction 
IgE-mediated allergy affects people of all age groups across the world (1). Allergic reactions are 
triggered by a wide range of allergen sources including foods, stinging insects, house dust mite, 
pollens, moulds, drugs and animal dander, causing manifestations affecting many different organ 
systems. Although most are IgE mediated allergic reactions, there are overlapping presentations 
with other pathophysiologies (eg anaphylactoid reactions). Severity of reactions vary, both between 
episodes within the same individual and between different individuals (2). Symptoms range from 
mild, self-limiting local reactions to life-threatening anaphylaxis. Perception is critical, with different 
stakeholders often having very different views about the apparent severity of the same reaction. 
These differences are important because the severity of a reaction guides both the immediate and 
long-term management of the patient (3). It is therefore vital to be able to describe accurately the 
severity of previous reactions to optimize both immediate care decisions and ongoing patient 
management. Moreover, there is a need to grade severity, to standardize patient monitoring, to 
define severity in participants in clinical studies, such as immunomodulation therapy, as well as 
facilitate risk assessment and management by, for example, the food industry and public health 
authorities.   
 
Many scoring systems have been developed to describe the severity of allergic reactions for venom 
(4,5), food (6-11), drugs (12,13) and adverse reactions to allergen immunotherapy (14,15). Some 
specifically mention anaphylactoid reactions (12,13); at least some of these are likely to represent 
anaphylaxis (absence of specific IgE is not reported) and as so are included. Although these have all 
been developed to assist patients and healthcare professionals correctly manage reactions, there is 
considerable heterogeneity in the approaches employed in these systems. Consequently, we lack a 
single, standardized approach to quantifying the severity of allergic reactions to all triggers that can 
be used by all stakeholder. The European Union-funded iFAAM project, in collaboration with a task 
force of the EAACI Food Allergy and Anaphylaxis Initiative, critically reviewed the currently available 
systems, considered the challenges to generating scoring systems and proposed an approach to 
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developing a harmonized system to quantify the severity of allergic reactions. In addition, 
recommendations were made as to how such a new scoring system could be validated. Our ultimate 
aim is in due course to develop a new severity scoring system for allergic reactions that can be 
utilized in different scenarios, in order to improve patient care and facilitate the needs of other 
stakeholders.  
 
Why do we need a severity scoring system for acute allergic reactions?  
A severity scoring system for allergic reactions may assist clinicians in at least two ways: providing a 
summary of a reaction reported by a patient or carers and providing a summary of an allergic 
reactions within the context of a challenge or immunotherapy undertaken in a clinical environment. 
The score should contribute to determining appropriate emergency treatment plans. Other 
important stakeholders are likely to have somewhat different views as to why a harmonized severity 
scoring system is required for allergic reactions (Table 1). For example, a patient might better utilize 
a simpler system that can be readily recalled in an emergency and directly links to emergency 
therapy (Figure 1). Although the level of detail required by each stakeholder may vary, there is an 
intrinsic benefit in having a harmonized system that all stakeholders can utilize. This would facilitate 
communication in terms of the nature of specific reactions and how they should be managed. At its 
simplest level, a harmonized scoring system could divide allergic reactions into a small number of 
grades with very different severities on the basis of easily recognized symptoms and signs. Each 
major grade might have a number of subgrades to provide additional detail that might be useful to 
an allergy healthcare professional or researcher. A validated disease severity scoring system could 
be used both to standardize patient monitoring and to define patient cohorts in clinical studies. 
 
 
Figure 1. Illustration of how a severity scoring system could be used to guide the management of 
acute allergic reactions  
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As severity increases with increasingly severe symptoms, adrenaline is more likely to be indicated. 
The exact symptoms when adrenaline is indicated needs to be individualised for different patients 
and for different situations by their healthcare professional as each will have a different risk profile. 
The figure is only an illustration with different severity sequences seen for different allergens and 
different patients. Additionally therapies such as oxygen and corticosteroids may also be indicated. 
Figure reproduced with permission from Muraro et al (3).  
 
 
The meaning or perception of severity in relation to acute allergic reactions  
The term severity has different meanings to different subgroups of patients, to health care 
professionals, researchers, the food industry, public health authorities or other stakeholders. All 
these perspectives need to be explored to understand the differing needs and concerns of each of 
these groups. A dictionary definition describes severity “as the degree of affliction suffered due to a 
condition or stressor” or “the degree of pain or harm from a medical condition”.  A severe reaction 
should be considered either as one causing disruption to the activities of daily life or an event that 
leads to an otherwise unanticipated healthcare utilization.  
 
It is important to recognize that “severity” is a continuum, which may be dynamic: a person having a 
mild reaction (e.g. mild angioedema) may progress to severe symptoms (e.g. bronchospasm) within 
a few minutes. There may be temporal differences in severity from one allergen exposure event to 
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another, possibly due to a genuine change in a patient’s clinical status, a change of dose of allergen 
or the addition of augmentation or co-factors that can exacerbate allergic reactions (16-18). 
Perceived severity depends on subjective interpretation of symptoms and can also vary depending 
on what else may be going on in an individual’s life (e.g. stress at work or home, other chronic 
disorders, level of risk aversion and co-factors), and on whether they are a patient or a carer. 
 
We believe it is helpful to consider severity of allergic reactions from the perspective of each of the 
key stakeholders.  
 
Allergic individuals and their carers: patients and their carers tend to under- or over-estimate the 
potential severity of severe allergic reactions and they may not seek medical help (19).  For example, 
clinical experience shows that families often consider angioedema in the context of an allergic 
reaction to be much more significant than mild wheeze; their allergy-experienced physicians are 
likely to disagree considering wheeze to be more severe (and potentially life-threatening). Patients 
and their carers may be used to wheezing with viral infections and therefore treat allergen-induced 
wheezing with their usual asthma treatments not appreciating that, in this context, the 
bronchospasm and resulting symptoms may worsen rapidly. Any disruption to daily life can be 
reasonably considered by the family to be a significant or severe event: for example, missing a day of 
school due to urticaria or visiting the emergency department due to anaphylaxis.  
 
Family doctors rarely encounter allergic reactions and may not have had training, the clinical 
experience or sufficient time within the consultation to assess their severity. Adrenaline 
(epinephrine) may be prescribed when it is not indicated or a patient may be referred to the 
emergency department when an allergic reaction is not potentially life-threatening. Conversely, the 
severity may be under-appreciated and the reaction only treated with antihistamines and 
corticosteroids instead of adrenaline (20).  
 
Emergency department physicians and first responders in the community may not appreciate the 
allergic origin of clinical scenarios that they encounter. The differential diagnosis for anaphylaxis is 
very broad (21). So, in the absence of any objective point of care diagnostic test, the constellation of 
symptoms and signs caused by severe multi-system allergic reactions (anaphylaxis) must be 
recognized if correct emergency treatment is to be initiated.  
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Allergy specialists are trained to recognize the clinical spectrum of allergic diseases and to 
pragmatically evaluate their patients’ previous reactions. An accurate evaluation of severity is 
required to determine emergency treatment and personalise care plans. Most allergists do not see 
their patients during acute allergic reactions so there is a need to accurately, but retrospectively, 
assess the potential severity.   
 
Health psychologists need to be able to separate the physiological symptoms of allergic disease from 
the psychological impact and determine the impact that is due to any psychological co-morbidities. 
Such an analysis has profound implications for correct treatment and management and for 
alleviating patient/parent anxiety and concerns. 
 
Food industry and public health bodies may consider a severe outcome to be any change in a 
person’s quality-of-life, unscheduled access to medical care, loss of time at work, school or studies.  
 
While there are clear differences between the perspectives and needs of these different 
stakeholders, there is also considerable overlap and this could feed into a harmonized approach. A 
harmonized severity scoring system for allergic reactions ideally needs to take into account the 
perceptions and needs of different stakeholders. Grades of severity should be distinct to facilitate 
their utilisation by patients, parents, healthcare professionals and other relevant groups. Ensuring 
that these grades make sense to other groups who may use the system will be a challenge, but it is 
essential for any proposed harmonized system that it is accepted by all stakeholders.   
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Table 1. Need for a harmonized severity scoring of acute allergic reactions according to different 
stakeholders  
Stakeholder Purpose Essentials of the system 
Patients and 
their carers 
Risk awareness, recognition of 
symptoms of allergic reaction, 
recognition of seriousness and 
decision of type of self-treatment, 
reassurance.  
Requires a simple, easy to remember 
system to facilitate direct linkage of 
presentation to management. 
Emergency 
department, 
family doctors 
and other 
healthcare 
professionals 
Assessment for acute and long term 
management according to their 
competences, decisions about need to 
refer to specialist, educational 
purposes 
Requires a simple, easy to remember 
system to facilitate emergency 
management. 
Allergy 
healthcare 
specialists 
Assessment for acute and long-term 
management, risk assessment and 
education of patients.  
To document the reaction in detail to 
allow documentation and 
communication.   
Food industry Increase awareness on anaphylaxis, 
risk assessment of products, risk 
management 
Client-facing sectors (e.g. restaurants) 
need a simple framework to manage 
allergic reactions. Risk assessors and 
managers need numerical scores that 
can be incorporated in probabilistic 
models of allergen risk.  
Public health 
authorities 
Increase awareness on anaphylaxis, to 
assess outcomes of health policies, 
funding allocation, health policy 
prioritization, cost-effectiveness 
assessment, improve allergic reaction 
codification, facilitate adrenaline 
availability, education on anaphylaxis 
management for lay people (e.g. 
teachers, children day carers, airline 
cabin crew) 
Require a simple, easy to understand 
system that can be used by non-
healthcare professionals. For regulators 
a more sophisticated numerical score 
incorporating probabilistic models of 
allergen risk would be required.    
Food, 
hospitality and 
catering 
industries 
Increase awareness on anaphylaxis, 
risk assessment of products, risk 
management 
The food industry (e.g. restaurants) 
need a simple framework to manage 
allergic reactions. Risk assessors and 
managers need numerical scores that 
can be incorporated in probabilistic 
models of allergen risk.  
Researchers Harmonise terminology in 
observational and interventional 
studies, aid comparison of data and 
interpretation of mechanistic studies 
 
System needs to document the reaction 
with increased granularity to allow 
definition, segmentation and analysis   
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What severity scoring systems are currently available? 
Different scoring systems have been proposed to assess the severity of acute allergic reactions. 
These address allergic reactions induced by food (6-11), drugs (12,13) hymenoptera stings (4,5) and 
adverse reactions to allergen immunotherapy (14,15). None of these was intended to be widely 
applied to all types of acute allergic reaction, despite some having been extended in this way (22-26). 
Data obtained from both clinical trials (6,7,10,14) and emergency room visits or intensive care unit 
(ICU) admissions (4,5,12,22-25) have formed the backbone of reviews, position papers and 
consensus reports (9,26-28). However, these scoring systems classify severity in different grades 
using ordinal scales that are not equivalent across the different scoring systems. Methods range 
from valuing key symptoms and signs (5-7,13,23) to more complex algorithms e.g. including the 
exposure dosage (10,22), fulfilment of 2-or-more criteria (4,29), summation of symptoms to assess 
severity (14,20) or related to number of organs involved and treatment plan (11). Furthermore, 
some of the classification systems only cover the most severe allergic reactions (i.e. anaphylaxis) 
(5,15), while others are designed for a wider spectrum of reactions (9,31,32). 
 
Almost all current scoring systems are organ-specific, dividing symptoms and signs according to 
origin (i.e. the skin, respiratory, gastro-intestinal, cardio-vascular, and nervous system); there is less 
consistency in terms of which symptoms and signs are included. Skin symptoms usually include 
pruritus, urticaria, angioedema and flushing/rash. Gastrointestinal features consist mostly of 
subjective symptoms (e.g. oral allergy syndrome, nausea, and abdominal pain), emesis and 
diarrhoea. Cardiovascular features include change in heart rate (from tachycardia to cardiac arrest) 
and different grades of hypotension. Neurological features are less consistent, with grades of anxiety 
and consciousness (from reduced activity level to total loss of consciousness). The biggest 
discrepancies are found in respiratory symptoms where some only apply airway obstruction (14), 
while others incorporate different levels of laryngeal symptoms, wheezing, dyspnea, asthma, 
cyanosis and respiratory arrest (9). Symptoms from upper airways (i.e. nose and eyes) are covered 
by some (9,25,28) and excluded by others (4,12,23). No approach has included a full set of 
symptoms and signs and the heterogeneity of scoring of each symptom/sign is pronounced, with 
classification ranging from “present” to “mild/moderate/severe” to the 6-grade comprehensive 
Japanese ASCA-system (30) (not available in English). A more limited number of grades (e.g. mild, 
moderate and severe or give adrenaline/do not give adrenaline) may be more useful for patients and 
non-allergy specialists. However, for research purposes, and to inform and validate more simple 
systems, it may be preferable to have a numerical severity score with more gradations.  
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Comparison across historical approaches is difficult, but not impossible. Categorical scales would 
need to be recalculated into comparable numerical values, which would involve difficult decisions 
about interpretation and categorization of diverse symptoms. This would need to be addressed with 
caution since comparisons across historical approaches would undoubtedly involve other important 
differences, such as diverse study populations (community versus hospital), ages (children versus 
adults), and routes of exposure (food versus hymenoptera venom). Moreover, these comparisons 
would need to overcome some vague terms without clear definitions and the fact that none of the 
severity scoring systems is  validated nor were any specifically designed for the proposed 
comparisons.  
 
What are the challenges associated with developing a single unified severity scoring system for 
acute allergic reactions?  
The key problem in developing an allergic reaction severity score is the lack of a reliable, evidence-
based, gold-standard criterion standard that can be used as a reference for derivation and validation. 
This is one of the research needs being addressed by the iFAAM study (33) and may provide a better 
outcome measure to use in generating a severity score. This in itself would need validation across 
the breadth of clinical allergy. Extending these systems to all allergic reactions is challenging, not 
least because of possible bias from a non-representative sample, with implications for both 
reliability and validity.   Furthermore, the existing allergy nomenclature is far from being harmonized 
(34).  A better insight into the disease mechanisms underlying different allergic reactions and an 
endotype-driven approach (35) would help to develop a common methodology across the huge 
spectrum of allergic disease. The range of allergic triggers, clinical presentations and ages plus the 
potential geographic diversity creates issues with adequate validation of any scoring system in all the 
key target populations 
 
 
A proposed approach to developing a severity scoring system 
An ideal scoring system for the severity of allergic reactions would be based on easily and routinely 
recorded variables. It should be applicable to all patient populations and to any acute allergic 
reaction, regardless of the trigger.  A classification of severity of acute allergic reactions also should 
fulfil two underlying premises: (i) as the severity increases, the number of involved organ systems 
will usually increase, and (ii) cardiovascular, neurological, bronchial and laryngeal involvement are 
potentially life-threatening and therefore signify more severe reactions. Ideally, a severity scoring 
system would have two formats to deal with the two different premises that both have different 
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raisons d’être (see above). A continuous numerical system that takes into account the totality of the 
available clinical data and a simpler form with a small number of discrete grades. Scores from the 
two formats should each be able to be mapped onto each other. Additionally, scores associated with 
less severe symptoms or signs should be lower than scores associated with more severe ones. 
 
In the simpler format, severity would be classified into different grades. Such an approach would be 
mainly intended for the more “routine” clinical management of patients, for non-allergy specialists 
and perhaps patients. It is therefore suggested that only three grades are included: the mildest 
reactions (grade 1) would include isolated local reactions of the skin or mucosa at the first contact 
with the allergen; an intermediate grade (grade 2) would include reactions that involve more distant 
skin, upper airway and/or gastrointestinal tract; and then the most severe, potentially life-
threatening reactions (grade 3) would comprise cardiovascular, neurological, bronchial and/or 
laryngeal involvement (Figure 2). This 3 level classification system could, for example, be graphically 
represented with a 3 colour code, yellow-orange-red for grades 1 to 3 (see Figure 2) that would 
facilitate understanding and wide dissemination in the lay and non-specialist health care 
communities. It would also facilitate individualised management with patients with different risk 
profiles advised to use adrenaline at different grades.   
 
In the more nuanced numerical format, the proposed severity scoring system would facilitate the 
needs of researchers and provide a detailed description of, for example, food challenge outcomes. If 
the resulting score could be interpreted in relation to the simpler grading system, flexibility would be 
enhanced making it useful to a wider number of stakeholders. The score would be generated using a 
list of variables derived by consensus by a multidisciplinary panel of experts. A numerical weighting 
would be applied to each variable; this weighting could be derived in step 1 by expert consensus (a 
subjective score) and then in step 2 by utilising a large database of clinical data from patients 
experiencing acute allergic reactions (an objective score).  
 
A data-driven approach to generate an objective score must be incorporated as it is more likely to 
produce a valid model. This lends itself to being integrated into, for example, probabilistic models 
being developed for allergen risk management by the food industry (36). Such an approach would 
utilize a statistical system to determine which variables to use and the weighting to be applied to 
each of them. Constructing an objective score would require data from allergic reactions 
experienced by a large population of patients who have undergone a comprehensive clinical 
evaluation including all the clinical manifestations of the reactions and a confirmation of their allergy 
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diagnosis by the criterion standard diagnostic test. The challenge is that the severity of each allergic 
reaction needs to be quantified to provide an endpoint against which a model can be generated 
using the available clinical variables. Such a criterion standard measure for severity does not 
currently exist; the best approximate we have is likely to be a consensus severity assessment made 
by a large multidisciplinary group of experts.  
 
 
Figure 2. Proposed simplified classification of severity of acute allergic reactions according to the 
organ system involved 
Local reactions Systemic reactions 
Grade 1 Grade 2 Grade 3 
Isolated local allergic 
reactions of the skin or 
mucosa at the first contact 
with the allergen. 
Allergic reactions that involve 
skin away from the site of 
allergen contact, upper airway 
and/or gastrointestinal tract. 
Severe, potentially life-
threatening allergic reactions 
involving cardiovascular, 
neurological, bronchial and/or 
laryngeal symptoms and signs. 
Patients would be assigned to a grade according to their most severe symptom/sign, e.g. grade 2 
may include symptoms of grade 1 and grade 2. These grades would be generated using the approach 
described in the text. Grades would have the ability to be easily translated into clinical management, 
although individual patient characteristics and circumstances need to be taken into account so that 
different patients might be instructed to use adrenaline at different grades according to their risk 
profile.  
 
 
How should we validate a new harmonized severity scoring system? 
A new severity scoring system would need to be validated to ensure that it provided an accurate 
assessment of severity in different populations at different time points. There are a number of 
accepted steps in this process. 
 
Face validity Face validation of an acute allergic reaction severity score is a key step as it assesses 
whether the intended users are satisfied with and understand the system. Some preliminary work 
would be required to make a case that the existing multiple systems should be replaced by one 
harmonised system. It must be made very clear what the new measurement means in terms of 
benefits for the diverse stakeholders and what type of data and results the tool can - and cannot - 
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provide. For example, an international panel of diverse stakeholders could be asked to review the 
score to assess whether or not they feel that it is appropriate for their needs. Some refinement will 
probably be required to ensure that the approach is optimised for use in different clinical setting.  
 
External validation The refined new severity scoring system would ideally then need to be validated 
statistically using external data. Given the aim of developing one harmonized score, this would 
require extensive research and cover a number of different areas, such as assessing it against the 
use of adrenaline and high dependency care admission. This likely to prove challenging as both 
adrenaline use and admission vary between healthcare systems and physicians. Criteria for validity 
would need to be set in advance.  
 
Cross-sectional validity would focus on the ability of the scoring system to differentiate between 
those experiencing outcomes of varying severities and also in comparing predicted with actual 
observed outcomes using standard parameters developed to assess the validity of models.  An ideal 
score would need to function in different health settings worldwide, with different triggers, dosages 
and threshold values and in different age groups and languages.  
 
Longitudinal  validity is also important. For example, patients who have been treated with an 
effective immunomodulation therapy might expect to have less severe reactions after treatment 
although this might be complicated if their threshold/eliciting dose also changes (2). In this respect, 
the minimal clinically important difference (MCID) (i.e. smallest difference in the score associated 
with the severity of acute allergic reactions that can be differentiated by an expert allergist) needs to 
be calculated to assess the resolution of the scoring tool.  For clinicians and researchers alike, it is 
critical that the MCID score is a valid and stable measure. A low MCID value may result in 
overestimating the positive effects of treatment, whereas a high MCID value may incorrectly classify 
patients as failing to respond to treatment when in fact the treatment was beneficial.  
 
This validation work would require a large number of clinical databases where the scoring system 
could be assessed against the best available assessment of severity. Many such data sets already 
exist. Examples are anaphylaxis registers including the UK registry (37), central European NORA 
registry (38) and the North American FAAN registry (39):  hospital admission data would be available 
from the UK Imperial PICAnet (40) and the Malaga database (41). All of these databases would need 
to be carefully assessed in terms of their strengths and limitations, with a combination of datasets 
providing the best option.   
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Impact assessment  
Following derivation and external validation, it is critical to assess whether the new scoring system is 
used as intended and translates into improved clinical outcomes (e.g. improved decision making in 
reactions, reduced risk; better quality of life). It is also important to ensure that it does not result in 
important unintended consequences.  This is ideally assessed by using a randomized controlled trial 
(RCT) in which the new scoring system is compared with usual care; depending on the likely risk of 
contamination between intervention and control arms, a cluster design may be needed with 
different trial sites randomized to different arms (45). If a formal experimental design is not possible, 
a quasi-experimental design could be employed (e.g. an interrupted time series or a controlled 
before-after design) although it should be noted that these alternative approaches are inherently at 
increased risk of bias when compared to a RCT. 
 
Implementation  
Implementation requires local, national and international champions to facilitate the adoption of a 
new approach so that it becomes embedded in routine care, together with case studies to 
demonstrate its utility and value to various different stakeholders. This can be promoted with the 
incorporation of the tool into guidelines or other coding systems, and related efforts to promote 
diffusion and adoption. (42,43). Education of healthcare professionals and other community 
professional groups such as teachers is essential, as well as risk assessors and managers in public 
health authorities and the food, hospitality and catering industries alike. Information technology can 
also be utilized to promote a new approach by developing for example a decision support engine (44) 
that stakeholders can use. Finally, demonstrating that a severity scoring system improved clinical 
outcomes (e.g. better quality of life; reduced risk; improved decision making in reactions) on a 
population-based level, would promote the further take up of the approach.  
 
Summary and conclusions 
The accurate assessment and communication of potential severity of acute allergic reactions is 
important to patients, clinicians, researchers, food industry and public health authorities. Many 
severity scoring systems are available, usually within the context of one group of allergens sources. 
However, none of the scoring systems has been developed using the gold standard method for the 
development of measurement and/or prognostic tools. Furthermore, none of these scoring systems 
has been validated. A validated reaction severity scoring system is needed to standardize patient 
monitoring. We propose an approach to developing a harmonized scoring system for acute allergic 
reactions that is based on a data driven method, informed by clinical and patient experience as well 
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as by the perspectives of other stakeholders. We envisage two levels of details: an ordinal three 
grade based format and a continuous scoring system giving a continuum from mild to severe 
reactions that is clinically meaningful. This would allow the same system to be used by patients, 
clinicians, researchers, the food industry and public health regulators. The new approach would 
need to be tested for reliability and validity using gold standard methods in a range of settings and 
populations. We propose that common epidemiological, clinical observational and clinical 
interventional datasets should be collected to promote future collaboration, cross-validation and 
refinement of the severity scoring system. For a harmonized system to be successful, an 
implementation strategy would be required and its impact would need to be assessed. Finally, 
severity should be considered as just one of a range of important aspects of risk assessment and risk 
management of allergic diseases. To determine the optimal management of a reaction for a patient, 
assessed severity needs to be integrated with the clinical context, for example the dose of allergen, 
route of contact, rapidity of onset and other intrinsic (patient-related) and extrinsic factors.  
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